Epizyme, Inc.
$8.1M 46 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. reported $8,066,855.35 across General Payments, Research, and Ownership to 1,007 physicians and teaching hospitals across 3,195 transactions.
- $8.1M
- All-tracks total
- 3,195
- Transactions
- 1,007
- Recipients
- −$92.3K
- General Payments vs PY2023
Rhythm Pharmaceuticals, Inc. reported $8,066,855.35 across all CMS Open Payments tracks (General + Research + Ownership) to 1,007 physicians and teaching hospitals in Program Year 2024 - ranking #208 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $177,035.79, averaging $8.0K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer rhythm-pharmaceuticals-inc Rhythm Pharmaceuticals, Inc.
$8.1M · #208/1,925 · 0.1% industry · PY2024
- TOT $8.1M
- RANK #208
- SHARE 0.1%
- TXN 3,195
- RCP 1,007
- CAT 6
- GEN $177.0K
- ΔGEN −$92.3K
- TOP1 11.3%
- PY 2024
Volume peers
Nearest volume peer: Epizyme, Inc. ($8.1M)
Rhythm Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Rhythm Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $92.3K (−34.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: RHYTHM PHARMACEUTICALS, INC.PY2023: RHYTHM PHARMACEUTICALS, INC.PY2024: Rhythm Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $269,360.71
- PY2024
- $177,035.79
What the Data Shows for Rhythm Pharmaceuticals, Inc.
Rank #208 of 1,925 companies in CMS Open Payments for 2024 belongs to Rhythm Pharmaceuticals, Inc., which reported $8,066,855.35 across 3,195 transactions to 1,007 recipients - a comparatively small 0.1% slice of all industry payments reported nationwide for the year. Averages work out to $2.5K per transaction and $8.0K per recipient.
Of the 6 general-payment categories charted below, "Honoraria" is the largest at $68.7K across 49 transactions, 38.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Honoraria" leads Rhythm Pharmaceuticals, Inc.'s 6-category general-payment breakdown at $68.7K, 38.8% of the reported total.
Rhythm Pharmaceuticals, Inc. reports 6 general-payment categories - the top three are Honoraria (38.8%), Consulting Fee (21.0%), and Food and Beverage (15.5%). The remaining 3 categories make up 24.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Rhythm Pharmaceuticals, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $68.7K | 49 | 38.8% |
| Consulting Fee | $37.1K | 24 | 21.0% |
| Food and Beverage | $27.5K | 865 | 15.5% |
| Travel and Lodging | $22.6K | 43 | 12.8% |
| Grant | $20.0K | 1 | 11.3% |
| Education | $1.2K | 25 | 0.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $69,486.24 (39.2%) of $177,035.79 in this company's General Payments records across 681 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Rhythm Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Childrens Hospital Colorado
$20,000.00 across 1 reported transactions
- 2
Jose Gamez
$14,591.31 across 21 reported transactions
- 3
Jennifer R Paisley
$13,804.14 across 15 reported transactions
- 4
James Swain
$11,660.18 across 7 reported transactions
- 5
Vidhu Thaker
$9,430.61 across 13 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Rhythm Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Rhythm Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Rhythm Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Macrogenics, Inc.
$8.2M 16 recipients
Compare payment profiles
Applied Medical Corporation
$8.0M 5 recipients
Compare payment profiles
Optimotion Implants, LLC
$8.0M 6 recipients
Compare payment profiles
Lightforce Orthodontics, Inc.
$8.3M 2,676 recipients
Compare payment profiles
Beckman Coulter, Inc.
$8.3M 469 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.